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Abstract
Breast cancer is the most common cancer among American women, except for skin cancers. About 12 % women in
the United States will develop invasive breast cancer during their lifetime. Currently one of the most accepted model/
theories is that ductal breast cancer (most common type of breast cancer) follows a linear progression: from normal
breast epithelial cells to ductal hyperplasia to atypical ductal hyperplasia (ADH) to ductal carcinoma in situ (DCIS),
and finally to invasive ductal carcinoma (IDC). Distinguishing pure ADH diagnosis from DCIS and/or IDC on mam‑
mography, and even combined with follow-up core needle biopsy (CNB) is still a challenge. Therefore subsequent
surgical excision cannot be avoided to make a definitive diagnosis. MicroRNAs (miRNAs) are a highly abundant class of
endogenous non-coding RNAs, which contribute to cancer initiation and progression, and are differentially expressed
between normal and cancer tissues. They can function as either tumor suppressors or oncogenes. With accumulating
evidence of the role of miRNAs in breast cancer progression, including our own studies, we sought to summarize the
nature of early breast lesions and the potential use of miRNA molecules as biomarkers in early breast cancer detec‑
tion. In particular, miRNA biomarkers may potentially serve as a companion tool following mammography screening
and CNB. In the long-term, a better understanding of the molecular mechanisms underlying the miRNA signatures
associated with breast cancer development could potentially result in the development of novel strategies for disease
prevention and therapy.
Background
Breast cancer is one of the most commonly occurring
cancers among American women and is the second leading cause of cancer-related deaths. Approximately 1 in
8 American women (12 %) will develop invasive breast
cancer in their lifetime, and it is estimated that there
will be 231,840 new cases of invasive cancer, 60,290 new
cases of noninvasive, in situ cancer, and 40,290 deaths
resulting from breast cancer in 2015 [1]. With the current focus on early detection and increased utilization of
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mammography, more and more non-malignant lesions,
such as atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), atypical lobular hyperplasia (ALH),
and lobular carcinoma in situ (LCIS), are detected. These
lesions are considered one of the most significant risk
factors for developing invasive carcinoma [1].
Although the death rates from breast cancer continue
to decline as a result of the increased utilization of mammography, it is not a definitive early screening tool due
to its limited sensitivity and specificity [2]. Fayanju et al.
reported that about 40 % of the 9000 registrants surveyed
refused to use mammography due to “fears of cost,” while
another 13 % refused to use it due to “mammogramrelated pain [3].”
Over the past decade, research has largely shifted focus
from mRNA biomarkers to microRNAs (miRNAs) as
a new potential screening biomarker for breast cancer.
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In numerous studies, including our own, researchers
have found miRNAs to be aberrantly expressed in tissue and serum/plasma in patients with breast cancer
[4–6]. Although the role of miRNAs in carcinogenesis is
unclear, evidence suggests that miRNAs are involved in
the initial development and progression of breast cancer
by modulating the expression of their target proto-oncogenes or tumor suppressor genes (TSG) at the posttranscriptional level [4]. We, as well as others (FFPE and 638
paper), have identified numerous miRNAs that are aberrantly expressed during breast cancer progression, indicating that miRNAs may serve as a new noninvasive,
cost-effective screening tool, as well as a companion tool
to be used in conjunction with mammography for more
accurate and specific diagnoses [5, 6]. Furthermore, there
are now ongoing studies on differential miRNA expression among different pathological stages of breast leisons:
ADH, DCIS and IDC [6].
To distinguish pure ADH diagnosis from advanced
lesions, such as DCIS and/or IDC following a mammography, and even combined with follow-up core needle
biopsy CNB is still a challenge. In this review, we summarized the nature of early breast lesions and the potential
use of miRNA molecules as biomarkers in early breast
cancer detection. In particular, miRNA biomarkers may
potentially serve as a companion tool following mammography screening and CNB. In the long-term, a better
understanding of the molecular mechanisms underlying the miRNA signatures associated with breast cancer
development could potentially result in the development
of novel strategies for disease prevention and therapy.
Linear model of breast cancer progression

The relationship between ADH, DCIS, and invasive cancer is not fully understood. Historically, breast cancer
was viewed as a progression from normal epithelial cells
to hyperplasia (with or without atypia), to in situ carcinoma, eventually resulting in invasive carcinoma and
metastasis. The most widely accepted model of breast
cancer development at the present time is that ductal
cells undergo a neoplastic transformation which starts
from normal epithelium to flat epithelial atypia (FEA),
evolving to atypical ductal hyperplasia (ADH), into ductal
carcinoma in situ (DCIS), and finally, into invasive ductal
carcinoma (IDC). This model is supported by genomic
and immunohistochemical data which shows distinct
features at each stage in development [7]. The current
understanding of breast cancer development supports
this model, placing invasive cancer at the end of a multistage transition from normal breast epithelium; however,
recent discoveries in molecular genetics and immunohistochemistry have highlighted the complexity of the process, identifying many different and divergent pathways
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resulting in invasive cancer. Cancer cells undergo their
characteristic changes over a significant timeframe, as
genes are activated and inactivated in a series of steps [8].
Over the course of tumorigenesis, these various cellular
and genetic changes present as pathologically distinct
entities.
Via a model of continuation, including FEA, ADH,
DCIS, and IDC, is supported by morphological, epidemiological, and immunohistochemical data, as well as
genomic and transcriptomic studies. Patterns of genomic
changes in DCIS, which parallel those occurring in IDC,
have been previously discussed. FEA and ADH also demonstrate similar distinct genetic changes, which overlap
with some of those of low-grade DCIS [7]. Notably, the
current evidence supports ADH as the precursor for
low-grade, but not high-grade, DCIS; the latter which
is believed to have a distinct progression, which may
include adenosis. Furthermore, there is evidence for progressive allelic damage from stages of ADH to DCIS and
finally IDC [8].
The current clinical approach used to prevent breast
cancer involves an attempt to diagnose at the earliest
possible time, which is the most easily treatable stage in
order to maximize the chances for positive outcomes.
Thus, improving our understanding of early stage cancers, as well as pre-neoplastic processes in the breast,
is crucial to improving future therapy. ADH represents
a crucial pathological stage in the transition from what
is considered normal to what is considered cancerous
in ductal cells. Ductal subtype accounts for 40–75 % of
diagnosed breast cancer cases [7]. We are currently aware
of many of the molecular biomarkers that may be indicative of a development from normal breast epithelium to
ADH, which will be discussed in detail below. Despite
our current capabilities, it is important to recognize that
ADH is not an obligate precursor to in situ or invasive
cancer, as noted by Kuerer, as only 14–50 % of women
with ADH or DCIS will develop invasive cancer in their
lifetime if left untreated [9]. Additionally, there have been
studies that show the changes of molecular markers that
occur during the DCIS stage actually contribute to the
invasive characteristics of cancer. Therefore, continued
efforts to understand the linear view of breast cancer
progression and, in particular, what causes this development from normal, to premalignant, to malignant stages
will offer necessary information in efforts to develop new
effective treatments.
Distinction between ADH and DCIS

It is important to recognize the differences between ADH
and DCIS, as they are both noninvasive lesions with several overlapping characteristics. ADH is a benign breast
condition characterized pathologically by some, but not
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all. ADH is seen in 1–9 % of core needle biopsies [10],
but is clinically noteworthy as a marker for risk of future
breast cancer development, and for its frequent association with DCIS and invasive carcinoma upon surgical
excision. ADH is now considered a non-obligate precursor for low-grade DCIS; in fact, the distinction between
ADH and DCIS is often unclear, causing diagnosis to
vary among institutions.
Although the distinction between ADH and DCIS is
unclear, DCIS is often categorized as non-invasive breast
cancer. Histologically, DCIS shows disorganized ductal
cells as opposed to ADH, which exhibits normal duct
cells with plugged lumens. The ADH is usually defined
as a mass less than 2 mm in size, while DCIS is greater
than 2 mm. Additionally, low-grade DCIS is defined as
a mass that includes two or more breast ducts [7]. Thus,
DCIS is often categorized as the following stage of ADH.
If DCIS is not surgically removed, it carries a higher risk
of becoming invasive cancer than ADH. DCIS also has a
higher rate of recurrence, at 30 % within the 5–10 years
after initial diagnosis [8].
Pathological findings

Mammographic screening, which has resulted in a
reduction in mortality rates due to breast cancer, has also
led to increased diagnosis of benign, non-palpable breast
lesions, including atypical, high-risk lesions [11]. ADH,
for instance, is diagnosed in the breast most often via
core needle biopsy or surgical excision. Historically, ADH
was a diagnosis of exclusion; the diagnosis was reserved
for lesions whose cells resembled low-grade DCIS but did
not fulfill all criteria for DCIS [12]. Though the criteria
for a diagnosis of ADH have been refined, histopathological distinctions between ADH and some low-grade DCIS
remains problematic. Diagnosis is primarily quantitative,
as cellular appearance is similar. Distinction between
ADH and DCIS is based on size and involvement, as
mentioned above.
Current diagnosis of ADH involves examination of
three variables: architectural pattern, cytology, and disease extent [13]. The cells of ADH are small to medium
sized, round, cuboidal, or polygonal shaped, regularly
arranged, and hyper-chromatic with evenly distributed nuclei and only small, singular nucleoli. Small foci
of necrosis are uncommon, yet may be present and do
not necessarily indicate DCIS [13]. Monotonous cells,
uniformly spaced with rigid secondary spaces, and lowgrade nuclei, characterize cells of both ADH and DCIS.
Regardless of lesion size, partial involvement of spaces
supports a diagnosis of ADH. The diagnosis of DCIS is
generally only made when a lesion meets these criteria:
either a diameter greater than 2 mm or more than two
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separate duct spaces, as these have been associated with
increased risk for breast cancer [14].
It has been noted that ADH is thought to lie on a histopathological spectrum between usual hyperplasia (lacking atypia) and low-grade DCIS. Usual hyperplasia differs
in appearance from ADH in variability of cells, indistinct
cell borders, and nuclear overlap, with irregular secondary spaces [15].
Due to the similarities in cellular appearance, particularly between ADH and low-grade DCIS, as well as the
small size of cores resulting from minimally invasive
breast biopsy, pathological diagnosis remains complicated. In fact, accurate diagnosis of ADH requires morphological, histological, and architectural size criteria
of a lesion, which may be interrupted by core biopsy
placement [13]. For this reason diagnosis is not always
reproducible between pathologists, and many argue that
accurate diagnosis of ADH can only be made from excisional biopsy. In a study involving six experienced pathologists who reviewed cases of usual ductal hyperplasia
(UDH), ADH, and DCIS, all six were able to reach consensus on only 58 % of the cases [15]. There has, to date,
been no biomarker identified that is more useful than
histopathologic diagnosis, though epigenetic changes
associated with ADH and DCIS have been the subject
of much recent research (see below “Biological findings”
section) and may aid in the development of a reliable
diagnosis in the future.
Clinical implications

The advent of population-based mammography screening has led to the increased detection of invasive breast
cancers as well as a larger number of non-invasive cancer
precursors, such as DCIS, and non-cancerous, high-risk
lesions such as ADH. Though some consider ADH to be
associated with over diagnosis, clinical diagnosis of ADH
has two important implications:
(1) In approximately 20–50 % of ADH cases an immediately adjacent cancer is found upon surgical excision,
and as a result excision is recommended for all cases
[16]. (2) Diagnosis of ADH is associated with a 4–5
times increased risk of development of breast cancer at
a median follow up of 17 years, a risk which is increased
to 8–10 times as likely in women whose family history
includes a primary relative with breast cancer [17].
Risk assessment is important as it includes a need for
vigilant annual mammographic screenings and requires
annual breast MRIs; these preventative measures may
include the consideration of utilizing chemopreventative agents such as Tamoxifen, which have been shown to
reduce the risk of developing breast cancer. Additionally,
the National Surgical Adjuvant Breast and Bowel Project
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found that Tamoxifen can reduce risk of breast cancer by
approximately 50 % in high-risk women, and has showed
an astounding 86 % decrease in incidents of breast cancer among women with a history of ADH. These findings
support the importance of reliable ADH diagnosis procedures, as the utilization of chemoprophylaxis selective
estrogen reuptake modulators (SERMs) to treat breast
cancer may be an effective tool in reducing mortality
[18].
In the case of a suspicious lesion sampled by CNB
which results in a diagnosis of ADH, standard followup care is currently the surgical excision of the lesion for
all patients, due to risk of associated cancer foci. Adjacent breast cancer is found in 18–48 % of cases with a
14-gauge needle and 19–25 % with an 11-gauge needle,
with some estimates even higher [10]. Unfortunately, this
practice subjects patients to the risks associated with surgery, discomfort, and what may be unnecessary cost, as
the majority patients with ADH do not have an associated carcinoma and many will not develop breast cancer
in their lifetime.
Current difficulties in the clinical management of ADH
are the inability to reliably assess risk, or the presence of
an adjacent cancer, and to identify prospective patients
who may not require surgical excision. Many studies
have been conducted to identify factors associated with
upgrade to cancer upon excision, and, although predictors have been identified, none are yet considered reliable enough to justify forgoing treatment for an ADH
patient. Generally, ADH found in more than two foci
is a significantly more reliable predictor of DCIS upon
excision than when found in less than two foci. In one
study, 39.0 % of cases (16/41) of ADH in more than two
foci versus 7.3 % with ADH in less than two foci had
an associated DCIS. In the same study, the lowest risk
group identified, with no associated DCIS, exhibits one
or two foci of ADH, micro-calcifications in the lesion,
and all calcification removed by biopsy (confirmed by
post-biopsy imaging) [17]. Many clinics have been able to
identify lower-risk subtypes of ADH that may have a risk
of associated DCIS of less than 2 %, which is the same
criterion that indicates a need for imaging follow-up
for BIRADS-3 lesions [19]. However, the upgrade rates
remain too high to support only surveillance of these
atypical lesions, as a breast imaging-reporting and data
system (BIRADS) score of B3 would indicate [13]. Further research aimed at identifying reliable predictors of
breast cancer risk in ADH patients is needed in order to
improve the efficiency of therapeutic recommendations,
as well as to minimize anxiety and procedural risks.
Finally, it is important to mention that though the evidence supports surgical excision of every ADH lesion
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detected by CNB due to its frequent association with
carcinoma, atypia found on an excision margin is not
considered a risk factor for cancer recurrence, and as a
result, in these cases further surgery is not currently recommended [12].
Biological/molecular findings

Techniques used for classifying ADH and DCIS are not
always reproducible between centers, and because of this,
there have been replicated studies aimed at finding stable
biological and molecular markers for diagnosing ADH
and DCIS. In two of the studies, done by O’ Connell
et al. and Arpino et al. respectively, 45 % of ADH patients
and 77 % of DCIS patients share the loss of heterozygosity (LOH) in chromosome 16p and 17q with ipsilateral
breast cancer when harvested from the same breast.
However, the percentage drops to 42 % in ADH and 70 %
in DCIS when harvested from non-invasive breast. The
rate of LOH was low at individual loci in ADH, which
suggests that these individual lesions may be genetically
heterogeneous. Furthermore, LOH was more common
in DCIS than in regular hyperplasia, which further indicates that DCIS is a more advanced stage in malignant
evolution [20]. Because LOH has been identified in ADH,
DCIS and IDC lesions with similar frequency in a study
done by Arpino et al., this supports the idea that ADH is
more of a clonal lesion and belongs in the same spectrum
as in situ carcinoma [17].
Another study done, by Ma et al., compared lasermicrodissected samples of ADH, DCIS, and IDC at the
transcriptome level. This study found that the samples
from these three stages are very similar in terms of transcriptome level, and that they may derive from the same
clonal origin, further supporting the claim that ADH is
a precursor lesion to DCIS. The study also found several
genetic alterations that occur in the ADH cells that persist through the DCIS and IDC stages; this analysis, however, did not identify the genetic changes that are distinct
to each pathological phase of breast cancer, suggesting
heterogeneity [19].
miRNA as the new biological/molecular marker

Although breast cancer research using genetic markers
has showed ADH to be a definite genetic precursor to
DCIS and IDC, it has also proved to be difficult in distinguishing one pathological phase of breast lesion from
another. Recent years, there have been many studies that
have found miRNA expression dysregulation between
normal, ADH, DCIS and IDC (Tables 1 and 2) [5]. Additionally, the expression of miRNAs can be measured via
tissue, plasma, and serum. miRNAs are physiologically
functional in regulating oncogene or tumor-suppressor
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Table 1 Serum, Tissue, and Plasma miRNA expression changes in resection samples in breast cancer
Sample type
Serum

Plasma

Cancer vs. normal

Expression

DCIS/ IDC vs. normal

Expression

miR-451

Down

miR-155

Up

miR-148a

Down

[4]
[4]

miR-27a

Down

[4]

miR-30b

Down

[4]

miR-182

Up

miR-155

Down

[21]
miR-19a

Up

[22]

miR-181b

Down

[22]

miR-24

Down

[22]

miR-15a

Up

[23]

miR-107

Up

[23]

miR-425

Up

[23]

miR-139-5p

Down

[23]

miR-143

Down

miR-365

Down

[23]
miR-181b

Up

[23]

miR-155

Up

[23]

miR-1

Up

[23]

miR-133b

Up

[23]

miR-92a

Up

[23]

miR-18a

Up

[23]

miR-145a

Down

[23]

miR-29-b2

up

miR-155

Up

miR-197

Up

miR-205

Up

[24]
miR-24

Up

[24]
[24]

miR-195

Down

[22, 25]

miR-205

Down

[22, 25]

miR-148b

Up

miR-376c

miR-409-3p

miR-92a

Serum + tissue

References

Up

Up

Up

miR-132-5p

Down

miR-125b-1-3p

Down

miR-34c-5p

Down

miR-382-3p

Down

miR-485-5p

Down

miR-323b-3p

Down

miR-598-3p

Down

miR-224-5p

Up

miR-1246

Up

miR-184

Up

miR-571

Down

miR-376c

Up

miR-139-3p

Down

miR-801

Up

miR-206

Down

miR-193a-3p

Down

miR-424

Up

miR-184

Up

miR-409-3p

Up

miR-376a

Up

miR-526b

Down

miR-519a

Down

miR-148b

Up

miR-190

Up

miR-127-3p

Up

[26, 27]

[28]

Fu et al. Cell Biosci (2016) 6:6

Page 6 of 9

Table 1 continued
Sample type
Plasma + tissue

Tissue

Cancer vs. normal

Expression

DCIS/ IDC vs. normal

Expression

References

miR-16

Up

[27]

miR-27a

Up

[27]

miR-150

Up

[27]

miR-191

Up

[27]

miR-200c

Up

[27]

miR-210

Up

[27]

miR-451

Up

[27]

miR-145

Down

[23, 27]

miR-21

Up

[23, 29]

miR-145

Down

[23]

miR-221

Down

miR-155

miR-30e

Up

Up

miR-10

Down

miR-29a

Up

[30]

miR-21

Up

[6, 30]

miR-99a

Down

[31]

miR-151-3p

Up

[31]

miR-145

Down

[31]

miR-210

Up

[31]

miR-10b

Down

[32]

miR-125b

Down

[32]

miR-132

Down

[32]

miR-145

Down

[32]

miR-154-3p

Down

[32]

miR-382-3p

Down

[32]

miR-409-3p

Down

[32]

miR-638

Down

[5, 6]

miR-200a

Down

[33]

miR-132

Down

[32]

miR-638

Down

[5]

miR-140

Down

[30, 34, 35]

miR-671-5p

Down

[6]

miR-183

Up

[6]

miR-200b

Up

[6]

miR-200c

Up

[6]

miR-557

Down

[6]

miR-1207-5p

Down

[34]

miR-874

Down

[34]

miR-556-3p

Up

[34]

miR-575

Down

[34]

miR-20a

Up

[34]

miR-15a

Up

[34]

miR-1202

Down

[34]

miR-141

Up

[6, 34]

miR-19b

Up

[23]

miR-1925

Down

[23]

miR-107

Up

[23]

miR-127-4b

Up

[23]

miR-1268

Down

[23]

miR-106b

Up

[23]

miR-634

Down

[23]
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Table 2 Tissue miRNA expression changes in resection
samples of ADH patients versus normal breast tissue
MiRNA

ADH regulation

miR-1275

Down [34]

miR-638

Down [34]

miR-572

Down [34]

miR-671-5p

Down [34]

miR-183

Up [6]

miR-141

Up [6]

miR-21

Up [6, 34]

miR-200b

Up [6, 34]

miR-200c

Up [6]

miR-15b

Up [23]

miR-183

Up [23]

miR-30d

Up [23]

genes (TSG), and thus, down-regulated or up-regulated
miRNAs can influence the activity of oncogene or TSG,
which in turn can affect tumorigenesis [5].
miRNAs are a class of regulatory RNAs that act to
repress the gene expression at the posttranscriptional level.
They normally bind to their target mRNAs via base-pairing
interactions, which results in either degradation of the target mRNA or inhibition of translation via storage. The miRNAs often bind to the mRNAs within the 3′ untranslated
region (UTR) of the target genes [36]. They are involved
in various biological processes that are necessary for the
maintenance of normal physiological state. In relation to
breast cancer, various miRNAs, such as miRNA-200c, are
responsible for the regulation of the genetic expression of
angiogenesis, apoptosis, proliferation, cell-to-cell adhesion,
etc. [37]. Thus, dysregulation of miRNAs expression can
lead to dysregulation of cell cycle and growth, which may
cause uncontrolled tumor growth [26].
Unlike genetic biological markers, miRNAs hold promise as a future screening marker for breast cancer because
they can be measured not only from tissue, but also from
serum or plasma. Three separate studies done by Sochor
et al., Cuk et al., and Li et al., showed that miR-155, miR19a, miR-181b and miR-24, which all act to repress TSG,
have been up-regulated in DCIS and IDC compared to
normal and ADH in serum. They also found that miR571, miR-206, miR-193a-3p, miR-526b, miR-519a, which
all act to repress oncogene, have been down-regulated
in ADH, DCIS and IDC compared to normal in plasma
(Table 1). Such findings support the idea that the levels
of miRNA collected in a patient’s serum or plasma are
not only a possible diagnostic tool for breast cancer, but
that it can also be a classification tool used to differentiate between ADH, DCIS and IDC if coupled with tissue
biopsy as a confirmatory test [22–32].

However, the miRNA expression levels measured
from tissue, serum, and plasma are not necessarily consistent. In a study done by Zhu et al., over 174 miRNAs
were expressed differently between breast cancer tumors
and the normal tissue, but only 109 miRNAs differed in
expression level between serum from patients with breast
cancer and healthy individuals [28]. Among those miRNAS, only ten were common miRNAs (Table 1). Furthermore, the study found that the change in expression
pattern of miRNA between healthy individuals and individuals with breast cancer are opposite in serum and tissue samples in 28 miRNAS [28]. Due to inconsistencies in
expression levels of miRNAs in various sample mediums,
miRNA biomarkers should be developed tissue-specific.

Conclusions
With the linear model of breast cancer development, it is
accepted that a breast lesion will develop as follows: ADH
to DCIS to IDC. With the advent of population screening with mammography, early diagnosis of breast lesions
has been possible, however differentiating between the
benign ADH and precancerous DCIS or IDC remains
illusive. The presence of ADH is known to be a significant
factor for the development of breast cancer; however at
this time, there are currently no clinical, morphological,
or biological markers that can be used to reliably predict
whether a premalignant lesion will progress to breast
cancer. Using miRNA levels found in serum, plasma,
and tissue as a diagnostic and classification tool seems to
have a promising future, as there have been hundreds of
miRNA identified to play a role in breast cancer. We, as
well as other researchers, have shown there are distinct
miRNA patterns to distinguish normal breast epithelium
from cancerous tissue as well as from DCIS/IDC, and
from ADH. Although the consistency of miRNA expression changes among serum, plasma, and tissue samples
still need to be proven, it does not preclude the idea that
miRNA biomarkers may serve as comparison tool for
mammography as a new, inexpensive, non-invasive diagnostic tool in the future.
Patients diagnosed with a lesion on mammography are
encouraged to undergo resection, however ADH is not
malignant and does not need to be removed.
It is of paramount importance to develop a new, inexpensive screening tool for breast cancer because it will
allow wider population, regardless of their socioeconomic status, to receive screening for breast cancer in
order to detect breast cancer early, and at the same time
to reduce false alarms. Thus, it will also allow for early
treatment and a reduction in deaths from breast cancer.
Therefore there is great value in utilizing miRNA biomarkers in differentiating ADH from advanced lesions as
a potential companion tool following mammography and
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CNB. In the long-term, an understanding of the molecular mechanisms underlying miRNA biomarkers associated with breast cancer progression could potentially
result in the development of novel strategies for disease
prevention and therapy.
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